Zobrazit minimální záznam

Characteristics, risk management and GMP standards of pharmaceutical companies in China

dc.contributor.authorChen, Hong
dc.contributor.authorQin, Lijian
dc.contributor.authorJiang, Cong
dc.contributor.authorQin, Mingshuai
dc.contributor.authorSun, Yanming
dc.contributor.authorLuo, Jingjing
dc.date.accessioned2023-12-19T08:55:57Z
dc.date.available2023-12-19T08:55:57Z
dc.date.issued2023
dc.identifier.citationFrontiers in Public Health. 2023, vol. 11, art. no. 1103555.cs
dc.identifier.issn2296-2565
dc.identifier.urihttp://hdl.handle.net/10084/151847
dc.description.abstractThe Good Manufacturing Practice (GMP) is one of the gold standards by which governments worldwide judge modern pharmaceutical companies’ production processes and product-safety standards. However, in all the nations, it is di cult to obtain real data about GMP inspection results, so conducting the related research is impossible. Taking advantage of a rare chance to obtain the on-site GMP inspection results in China, we have been able to initiate an empirical analysis of how company characteristics and risk management acs
dc.language.isoencs
dc.publisherFrontiers Media S.A.cs
dc.relation.ispartofseriesFrontiers in Public Healthcs
dc.relation.urihttps://doi.org/10.3389/fpubh.2023.1103555cs
dc.rights© 2023 Chen, Qin, Jiang, Qin, Sun and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectpharmaceutical company characteristicscs
dc.subjectrisk managementcs
dc.subjectGMPcs
dc.subjectpharmaceutical company supervisioncs
dc.subjectChinacs
dc.titleCharacteristics, risk management and GMP standards of pharmaceutical companies in Chinacs
dc.typearticlecs
dc.identifier.doi10.3389/fpubh.2023.1103555
dc.rights.accessopenAccesscs
dc.type.versionpublishedVersioncs
dc.type.statusPeer-reviewedcs
dc.description.sourceWeb of Sciencecs
dc.description.volume11cs
dc.description.firstpageart. no. 1103555cs
dc.identifier.wos000954246800001


Soubory tohoto záznamu

Název:
2296-2565-2023v11an1103555.pdf
Velikost:
498.0Kb
Formát:
PDF
Zobrazit/otevřít

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam

© 2023 Chen, Qin, Jiang, Qin, Sun and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Kromě případů, kde je uvedeno jinak, licence tohoto záznamu je © 2023 Chen, Qin, Jiang, Qin, Sun and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.